Adverum Biotechnologies (ADVM) Proxy Filing summary

Executive summary

• Annual meeting scheduled for June 17, 2025, to be held virtually, with voting on five key proposals including director elections, auditor ratification, executive compensation, equity plan amendment, and stock option repricing.

• Board recommends voting in favor of all proposals, emphasizing the importance of equity compensation for talent retention and alignment with shareholder interests.

• Proxy materials and annual report are available online, and shareholders can vote via internet, phone, or mail.

Voting matters and shareholder proposals

• Election of three Class II directors to serve until 2028.

• Ratification of Ernst & Young LLP as independent auditor for 2025.

• Advisory vote on executive compensation (say-on-pay).

• Approval to amend and restate the 2024 Equity Incentive Award Plan, increasing the share pool by 2,100,000 shares.

• Approval to reprice certain outstanding stock options to the current market price.

• Board unanimously recommends voting for all proposals.

Board of directors and corporate governance

• Board consists of ten directors, divided into three classes with staggered three-year terms.

• Board diversity includes 20% women and 40% from underrepresented groups.

• Committees include Audit, Compensation, Nominating and Corporate Governance, and Research and Development.

• Corporate governance guidelines, code of ethics, and insider trading policy are in place.

• Directors are encouraged, but not required, to attend annual meetings.